Search

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation

The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).

Read more

EHA Research Conference 2025

Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques Diaz, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson, 
Özgen Deniz, Kimberly Stegmaier, and Nina Cabezas Wallscheid

Registration is now open

EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…

Read more

SWG educational activities

This SWG was established in January 2024. Educational activities will be added in due course.

Read more

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

Registration & accommodation

Registration is closed

Individual RegistrationHybrid registration fee includes:

Access to the scientific and educational sessions of the meeting
Networking opportunities to speak with the faculty during breaks and the welcome reception
Coffee/tea breaks on November 2-4 and lunches on November 3 and 4
Access to…

Read more

Kite and Gilead @EHA25 Virtual

We are proud to support the first ever EHA25 Virtual congress. Please join us & leading experts to learn about the latest in cell therapies and COVID-19.

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more